because it captures both quantity and dosage interval; however, claims database analyses and patient-reported adherence remain the most common methodologies employed due to the ability of conducting large studies quickly and at relatively low cost. 14, 15 Persistence refers to the time during which a patient remains on a prescribed medication after initiating therapy. While persistence can be measured directly by patient questionnaires and claims analyses, it may also be measured indirectly from discontinuation rates reported in observational and randomized controlled trials (RCTs). 11 While RCTs employ a structured program of care that may result in low discontinuation rates compared with the real-world patient experience, trends of discontinuation over time, as well as reasons for discontinuation reported in RCTs, may yield important information on persistence.
Many comprehensive literature reviews have been conducted on the adherence and persistence to chronic Medication adherence is often determined by a ratio of doses taken on schedule compared with the total number of doses prescribed over a specified period. 11 In observational studies, this ratio can be determined through pill counts conducted by an investigator or logged by a medication event monitoring system (MEMS). Pill counts provide an accurate measure of adherence by comparing the prescribed quantity of drug with the actual quantity of drug taken by the patient over a period of time. MEMS has the additional benefit of providing an electronic time stamp that measures whether the drug is taken at the prescribed dosage interval. 12 Another way to determine adherence is by calculating the medication possession ratio (MPR) or proportion of days covered (PDC) using pharmacy claims data. MPR is the sum of the days supply for all fill periods divided by the total number of days in that period. PDC is calculated as the number of days with drug on hand divided by the number of days in the specified time interval. 13 MEMS is considered perhaps the most precise measure of adherence Persistence n = 8
FIGURE 1

Results of Systematic Review (PubMed 1966-Present and EMBASE 1974-Present)
• Duplicates: n = 466
• Reviews: n = 248
• Nonmigraine studies: n = 177
• Other drugs: n = 98
• < 18 years old, pregnant, or elderly patients: n = 69
• Pharmacokinetic studies: n = 42
• Case studies: n = 30
• Incomplete or missing discontinuation data: n = 48
• Extension and post hoc analyses: n = 6
• Language not English: n = 4
• Expert opinion: n = 3
• Studies on relapse: n = 2 Observational Studies on Oral Migraine Prophylaxis Adherence and Persistence a member of a major therapeutic class of oral agents used as migraine prophylaxis (beta blockers, antidepressants, and anticonvulsants). Studies were limited to prospective and retrospective observational studies on adherence and persistence of migraine prophylaxis and RCTs of the 3 aforementioned migraine prophylaxis medications. Studies examining use for headache disorders other than migraine were excluded, as were editorials/commentaries, reviews, case studies, animal studies, cost-effectiveness studies, pharmacokinetic studies, and guidelines. Articles not available in English and studies conducted in children/adolescents (< 18 years of age), elderly, and pregnant subpopulations were also omitted.
Data Synthesis
Observational studies and RCTs were analyzed separately. Adherence and persistence data from observational studies were medications; however, none have been published on migraine prophylaxis to date. The purpose of this systematic literature review is to summarize all available evidence of adherence and persistence to 3 common oral medications used as migraine prophylaxis.
■■ Methods Search Methods
Potential studies were identified by searching the PubMed (1966 to July 1, 2011) and EMBASE (1974 to July 1, 2011) databases for "migraine prophylaxis" combined with the terms "adherence" OR "compliance" and "migraine prophylaxis" combined with each of the following medications: "propranolol" OR "amitriptyline" OR "topiramate" (Figure 1 ). The medications chosen for this review are the 3 most commonly used oral medications for migraine prophylaxis, and each is 
Persistence Data from Randomized Controlled Trials of Oral Migraine Prophylaxis (continued)
Observational Studies: Adherence Of the 6 observational studies that examined migraine prophylaxis adherence, 1 used electronic MEMS to assess adherence, 12 while 3 reported outcomes based on self-report, [16] [17] [18] and 2 used retrospective claims analysis to calculate MPR. 19, 20 Five of the 6 studies were conducted in the United States, with time horizons ranging from 4 to 56 weeks. The sixth study was conducted in Germany and used a time horizon of 80 weeks. All studies used a wide variety of medications from the 3 major therapeutic classes of oral migraine prophylaxis agents-anticonvulsants, antidepressants, and antihypertensives-except for 1, which restricted the study medications to anticonvulsants. 18 Medication dosage was not considered in any of the studies. Across studies, adherence ranged from 41% to 95% at 2 months and declined over time to 21% to 80% at 6 months and 35% to 56% at 12 months. Individual study data are shown in Table 1 .
Observational Studies: Persistence
Four open-label studies were identified that evaluated topiramate [21] [22] [23] or amitriptyline alone, 24 while 2 comparative studies evaluated divalproex and topiramate, 25 and flunarizine and propranolol. 26 Studies were conducted in Germany, [21] [22] [23] Austria, 24 Belgium, 26 the Netherlands, 27 and Brazil. 25 Dosages varied by individual patient but were within the range of approved FDA-labeled dose for migraine prophylaxis, where applicable. Persistence was also evaluated in 2 large claims database analyses that included a wide range of medications from the 3 major classes of oral migraine prophylaxis, without regard for dose. 27, 28 These studies report that persistence ranged from 41% to 88% at 2 months, 19% to 79% at 6 months, and 7% to 55% at 12 months. Individual study data are shown in Table 1 .
Randomized Controlled Trials: Persistence
Since persistence can be calculated as the inverse of discontinuation, persistence can be inferred from discontinuation rates reported in RCTs. Nineteen RCTs provided sufficient data on discontinuation, as part of trial design, among propranolol, amitriptyline, and topiramate. The populations of migraine patients were generally similar, as evidenced by the similar age and gender distributions and comparable recruitment criteria (inclusion/exclusion) across the RCTs reviewed. Differences were assumed to be negligible; therefore, results were pooled and weighted by sample size to calculate a weighted average discontinuation rate for each medication of interest (Table  3) . Although some studies evaluated medications other than those included in this review, only patients on propranolol, amitriptyline, topiramate, and placebo were pooled. Time horizons varied across studies, ranging from 8 weeks to 26 summarized as part of the systematic review. Discontinuation data from RCTs were pooled, weighted by sample size, and stratified by drug and length of study. Average persistence rates (1-discontinuation) and reasons for discontinuation cited in RCTs were examined for each medication.
■■ Results
Search Results
Searches returned a total of 1,254 articles, of which 788 were found to be unique. Abstracts were reviewed for 96 studies that met the inclusion/exclusion criteria, of which 48 were subsequently excluded because of incomplete or missing discontinuation data. The absence of data was, in part, caused by a number of crossover studies, especially among propranolol RCTs, that did not report discontinuation rates in the study results. A further 4 studies were available only in Spanish (n = 1), Portuguese (n = 1), or German (n = 2); 6 reported data on patients included in other studies (open-label extension studies or post hoc analyses); 2 examined relapse after discontinuing the study medication; and 3 were expert opinion. Included studies (N = 33) are shown in Table 1 , which lists observational studies that examined adherence and persistence, and Table 2 , which lists the RCTs of the 3 prophylactic medications and the rate of discontinuation reported in each study. Figure 2 as the proportion of patients who stayed persistent (calculated as 1-discontinuation at the end of the study time horizon). The primary reasons for discontinuation across the different medications were also compared and summarized in Table 4 as well as Figure 3 . The pooled data show that persistence declines rapidly over time, with nearly half of RCT participants discontinuing from clinical trials of amitriptyline and topiramate by 12-26 weeks (45% and 43%, respectively). Adverse events were the most common reason for discontinuation cited, especially among patients treated with topiramate (24%) and amitriptyline (17%). Individual study data from each RCT are available in Table 2 .
■■ Discussion
This review demonstrated a downward trend in migraine prophylaxis adherence and persistence over time that is similar to that seen for other chronic disease states. Adherence and persistence were shown to be below the acceptable threshold (< 80%) after 6 months among both observational and RCT data. While study heterogeneity limits the ability to compare across all available data, this review of the literature has produced several important findings. First, there was a substantially lower rate of discontinuation among RCTs evaluating propranolol compared with amitriptyline or topiramate. The reason for this low rate of discontinuation among patients taking propranolol is unknown. However, the propranolol RCTs were generally conducted earlier (1980s) than the other 2 medications reviewed, which may have influenced RCT design, data capture, or documentation of study discontinuation. In addition, the types of RCTs for propranolol are largely small studies, potentially reducing the discontinuation rate if trial participants were more closely managed. Aside from differences in study duration, RCTs were not adjusted for differences in study design, and this absence of adjustment may bias the results if there were systematic differences in the rate of discontinuation in amitriptyline, propranolol, and topiramate RCTs that are unrelated to the study drug. Counterintuitively, pooled discontinuation rates for the placebo groups across all studies had similar rates of discontinuation compared with amitriptyline and topiramate. However, when stratified by primary reported reason for discontinuation, placebo differs from active agents in the drivers of discontinuation. Placebo has very low rates of discontinuation because of adverse events and very high discontinuation for other reasons (including lack of therapeutic effect), while discontinuation of active interventions was mostly attributed to adverse events. 
Discontinuation Rates by Cause
Limitations
This review is subject to several important limitations. There are many oral agents used for migraine prophylaxis. For this systematic review, only the 3 most common oral medications were reviewed. However, the 3 medications described here are each a member of the 3 major therapeutic classes of oral agents used as migraine prophylaxis (anticonvulsants, antidepressants, and beta blockers) and thus may be somewhat representative of the therapeutic class as a whole. Another important note is that pooling results across studies may not be appropriate, given differences in study design, geographic region population, dosing, etc. For this reason, we refrained from combining the results of observational studies. The discontinuation rates and reason for study withdrawal from RCTs may not be generalizable to the real-world patient experience of these agents because of the structured program of care employed in clinical trials. We acknowledge that such bias exists, but that it is likely to produce a conservative estimate of persistence rates, as those enrolled in a clinical trial are potentially less likely to discontinue taking the drug. Furthermore, in 3 of the 14 observational studies, adherence was calculated using patient-reported data. While this methodology allows for convenient real-world data collection, it has been shown to overestimate adherence rates. 29, 30 Conversely, using MPR may underestimate adherence because some patients may have withdrawn from therapy because such therapy is no longer indicated. Migraine frequency and severity fluctuate over time in many patients, and some patients may discontinue prophylaxis because it is no longer warranted. Given the data available, we were unable to assess the ongoing clinical need for 
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prophylaxis and thus may underestimate persistence if a large proportion of patients withdraw from therapy because it is no longer indicated. Despite these limitations, we believe that this study helps provide a broad overview of adherence and persistence to oral migraine prophylaxis and highlight the need for future studies to investigate this topic.
■■ Conclusion
Observational studies as well as pooled data from RCTs support that oral migraine prophylactics have poor adherence and persistence. New options with improved tolerability and/ or fewer dosing intervals may improve patient adherence to oral migraine prophylaxis treatments. Adherence should be considered as an endpoint in future studies exploring the use of such therapies. Weighted Discontinuation Rate by Cause
